The study of Ropivacaine in perioperative analgesia and anti-tumor mechanism for lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070842

Enrollment

Unknown

Registered

2023-04-24

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Group of General Anesthesia:General anesthesia

Group of Nerve Block:Nerve Block

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age >20 years old; ASA grade ? - ?; VATS

Exclusion criteria

Exclusion criteria: History of local anesthetic allergy; Abnormal coagulation function; Puncture site infection; Immune system or endocrine dysfunction; Opioids; Non-steroidal anti-inflammatory drugs; Hormones or other immunomodulatory substances were pretreated.

Design outcomes

Primary

Measure	Time frame
vas score;Opioid consumption;	—

Secondary

Measure	Time frame
Adverse reactions (nausea, vomiting);	—

Countries

China

Contacts

Public ContactQiu Lan

The First People's Hospital of Changzhou, Jiangsu Province

qiulanmz@163.com+86 13915089989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026